Liver Diseases  >>  brivanib alaninate (BMS-582664)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivanib alaninate (BMS-582664) / ZAI Lab
NCT00355238 / 2006-001012-68: A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Checkmark P2 data
Feb 2011 - Feb 2011: P2 data
Checkmark P2 data - HCC
Jun 2010 - Jun 2010: P2 data - HCC
Completed
2
137
Europe, US, RoW
brivanib (active), BMS-582664
Bristol-Myers Squibb
Hepatocellular Carcinoma (HCC)
04/10
04/10

Download Options